COVID-19 therapeutics I: Drug combination for the therapeutic induction of T cells against COVID-19 (IndTCOVID-19) - clinical trial and immunomonitoring | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2021
2023
Known Financial Commitments (USD)
$1,238,847.36
Funder
Federal Ministry of Research, Technology and Space (BMFTR)
Research Location
Germany
Lead Research Institution
Eberhard Karls Universität Tübingen
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.

Authors
Tandler C, Heitmann JS, Michel TM, Marconato M, Jaeger SU, Tegeler CM, Denk M, Richter M, Oezbek MT, Maringer Y, Schroeder SM, Schneiderhan-Marra N, Wiesmüller KH, Bitzer M, Ruetalo N, Schindler M, Meisner C, Fischer I, Rammensee HG, Salih HR, Walz JS.
Publish Year
2024
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
DOI
10.1016/j.ijid.2023.11.009

View at Europe PMC

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome.